1 / 40

rUBELLA

Dr askari. rUBELLA. GERMAN MEASLES. RNA virus Abortion and sever congenital malformation in the 1 trimester Peak incidence in late winter and spring Minor importance in absence of pregnancy. Clinical manifestations. Mild febrile illness

wanda
Download Presentation

rUBELLA

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Dr askari rUBELLA

  2. GERMAN MEASLES • RNA virus • Abortion and sever congenital malformation in the 1 trimester • Peak incidence in late winter and spring • Minor importance in absence of pregnancy

  3. Clinical manifestations • Mild febrile illness • Generalized maculopapular rash • Artheralgia or arrthritis • Head and neck lymphadenopathy • Conjunctivitis

  4. Infectiuos period • Incubation period 12+13 days • Viremia precede clinical signs • Infectious period during viremia and 5_7 days of the rash

  5. Risk of fetal infection • 80% during first 12 weeks • 54% during 13_14 weeks • 25% during second trimester

  6. Sign and symptom • Eye defects:cataract,glucoma • Heart disease:PDA,pul artery stenosis • sensorineural deafness most common • CNS defects :microcephaly,developmentaldelay,mental retardation • Pigmentaryretionpathy • Neonatal purpura • Hepatosplenomegaly • Radiolucent bone dz

  7. Diagnosis • Diagnosis made with serology • Rubella isolated from :urin,CSF,nasopharenx • Enzyme linked immuno assay IGM 4_5 days after clinical dz or 8 weeks after appearance rash • Peak serum titer IGG demonstrated 1_2 weeks after rash or 2_3 weeks after viremia • High rubella IGG avidity in recarrent infection

  8. Some abnormality in sono • Fetal growth retardation • Ventricolomegaly • Intracranial calcification • Microcephaly • Microphethalemia • Meconium peritonitis • Hepatosplenomegaly • Cardiac malformation

  9. Management and prevention • No specific treatment for rubella • Avoidance of droplets for 7 days after rash • Vaccine in non pregnant women at child bearing age and hospital personels • Avoided vaccine 1 month before pregnancy and during pregnancy • No evidence that vaccine induced malformation<1%>

  10. Dr askari Varicella zoster virus

  11. Varicella zoster virus • Double stranded DNA herpes virus • Acquired predominantely during childhood • 95% of adults have serological evidence of immunity • Transmitted by direct contact or respiratory transmission • Incubation period is 10_21 days • Contagious from 1 day prior to the onset rash until lesion crusted over • 60_95%risk of infection after exposure in non immune women

  12. Clinical manifestations • 1_2 days flu like sx • Pruritic vesicular lesions crusted over 3_7days • Infection tend to be more sever in adult • Mortality is prodominately due to varicellapnemoniaperticulary in pregnancy • Pnemonia :fever,tachypnea,drycough,plureticpain,nodullar infiltration in CXR<like other viral pnemonia>

  13. Diagnosis • Usually diagnosed clinicaly • Tzank smear • Tissue culture • Direct fluorescent antibody testing • In fetus with nucleic acid amplification technique on amniotic fluid

  14. Fetal varicella infection • Chiken pox occure during first half of pregnancy fetus may developed congenital anomaly • Congenital infection after 20 weeks are uncommon

  15. Congeitalvaricellasx • Chorioretiniris • Microphethalemia • Cerebral cortical atrophy • Growth restriction • Hydronephrosis • Skin or bone defects

  16. Risk of congenital infection • 0.4% before 13 weeks • 2% 13_20 weeks

  17. Peripartum infection • Exposure before or during delivery poses a serious threat to newborn with attack rate 25_50% and mortality rate 25% • IgVZV should be administered to neonate born to mother who have clinical evidence of VZV 5 days before up to 2 days after delivery

  18. Exposure to virus • Exposed seronegative pregnant women need to given varizIG within 96hrs of exposure • Isolated this pregnant women from other pregnant women • Considered CXR • Most women require only supporative care • Pneumonia managed in hospital with IV fluid and IV acyclovir 500 mg/m2 or 10_15 mg/kg q8h

  19. vaccination • Live virus vaccine: • Varivax<1995> in adolescents and adults with no history of varicella with 2 doses given 4 to 8 weeks apart with 97%seroconversion • Zostavax <2006> not recommended for individuals younger than 60 years

  20. Thanks for your attention Thanks for your attention

  21. عدم وجود علائم اورژانس • اخذ شرح حال • تایید سن بارداری • انجام آزمایشهای CBC, BS, FL • مشاوره با خانواده و ارائه مشکل

  22. اقدام مطابق راهنمای شوک هموراژیک و القای زایمان • پلاکت کمتر از 100000 • فیبرینوژن زیر 100

  23. نتایج نرمال آزمایشات • تمایل مادر به ختم سریع بارداری • عدم تمایل مادر به ختم زودهنگام بارداری

  24. عدم تمایل مادر به ختم زودهنگام بارداری • کنترل هفتگی پلاکت و فیبرینوژن • انتظار تا 4 هفته از زمان مرگ برای شروع زایمان

  25. اقدام جهت ختم بارداری • انجام CT, BTدر شروع زایمان • انجام مشاوره داخلی در صورت اختلال CT , BT • انجام زایمان جنین مرده

  26. بررسی علل مرگ جنین • معاینه جفت وبند ناف وپرده ها • پاتولوژی جفت • ظاهر جنین • فتوگرافی و X-RAY از جنین • مشاوره خانواده جهت بارداری بعدی

More Related